Clinical Trial Update: Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study) [Phase 2]

View source ↗

Summary

The ZEAL Phase 2 trial evaluating the combination of Zibotentan and Dapagliflozin for liver cirrhosis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Cirrhosis

Drugs mentioned

• Dapagliflozin (dapagliflozin)
• Zibotentan (zibotentan)

Snippet

Sponsor: AstraZeneca | Conditions: Liver Cirrhosis | Phase 2 | Status: TERMINATED